Log in to search using one of your social media accounts:

 

Questionable Testing Common After Ovarian Cancer Therapy Questionable Testing Common After Ovarian Cancer Therapy

Despite evidence that cancer antigen 125 (CA-125) tests and CT scans for surveillance in ovarian cancer patients are not beneficial after treatment, the practice continues, according to a multicenter study.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news

Related Links:

Conclusions: We have stated the complex heterogeneity of ovarian cancer models, resembling primary tumors, agreeing with the argument that the cell line model for in vitro experiments must be carefully chosen. Our results also support that tridimensional culture could be a very helpful alternative in ovarian cancer research. Regarding EMT, a very important process for the development of this disease, some related biomarkers might be further characterized for their role in this disease development. PMID: 29774110 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Matsuoka T, Tsujioka H, Matsuoka S, Sorano S, Toyama A, Mori H, Yamamoto H, Nakamura S, Fukami T, Goto M, Matsuoka R, Eguchi F Abstract Retroperitoneal leiomyosarcoma is a relatively rare and aggressive tumor. Because of its rarity, it is difficult to arrive at a definite diagnosis preoperatively and to design an effective strategy. Here the authors report a case of peritoneal leiomyosarcoma in which diagnosis was difficult because the clinical course resembled that of ovarian cancer. A 77-year-old woman diagnosed with ovarian cancer underwent laparotomy. The excised tumor contained a necrotic polypoid mas...
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
CONCLUSION: Treosulfan might be an effective and well-tolerated treatment even in heavily pre-treated patients with metastatic breast cancer. PMID: 29767877 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
Authors: Yucel E, Ilter E, Aksungar FB, Celik A, Peker BH, Serifsoy E, Bozkurt S Abstract Ovarian cancer forms 4% of all cancers and approximately 23% of all gynecological cancers in women and is responsible for the 47% of deaths related to cancers of the genital tract of women. Tumor markers are the biochemical substances which can be detected in the presence of tumors. Generally they are either the products of tumoral tissues or secreted from the normal cells which are in the inter- action with tumoral ones. The present authors attempted to determine the efficacy of the tumor marker CA- 125 and HE4 to differentia...
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
CONCLUSIONS: Combination of PGA appears to be safe and very active against platinum-resistant/refractory ovarian cancer and merits further evaluation prospectively. A randomized phase II study (NCTO 1936974) is currently under way to confirm this important finding. PMID: 29767862 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
CONCLUSION: This study suggested that serum expression level of cytokines and chemokines correlate with progression of human ovarian cancer. The association of EGF, MCP-1, 6Ckine, IL-6, and TNF-α may contribute to increase diagnosis rate of malignant ovarian tumors. PMID: 29767861 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
Authors: Farghaly SA Abstract The standard of care for patients with recurrent ovarian cancer is platinum-based combination chemotherapy for those who relapse more than six months after completing adjuvant therapy. The use of biological agents such as bevacizumab has increased progression- free survival (PFS), but has not shown a significant increase in overall survival (OS). Immunotherapy treatment modality is being ac- tively pursued for patients with ovarian cancer. The goal of immunotherapy is to generate a tumor specific, T cell response that decrease residual disease, and protects against future recurrence. C...
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
Authors: Lee YJ, Chung YS, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT Abstract OBJECTIVE: The choice between primary debulking surgery (PDS) and neoadjuvant chemotherapy (NAC) in advanced ovarian cancer remains controversial. We evaluated NAC use in our center before and after results from a randomized trial were published, with the aim to determine the impact of changes in the neoadjuvant strategy on survival in advanced-stage ovarian cancer. METHODS: We retrospectively investigated the clinical course of 435 patients with ovarian, tubal, or peritoneal carcinoma (International Federation of Gynecology and Obstetric...
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
CONCLUSION: Survival benefit of LAR did not appear to be significant in EOC patients with grossly pelvis-confined tumors. PMID: 29770630 [PubMed - as supplied by publisher]
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
Authors: Suh DH, Chang SJ, Song T, Lee S, Kang WD, Lee SJ, Roh JW, Joo WD, Yoon JH, Jeong DH, Kim HS, Lee SJ, Ji YI, Kim HJ, Lee JW, Kim JW, Bae DS Abstract Since after 2006 when the first edition of practice guidelines for gynecologic oncologic cancer treatment was released, the Korean Society of Gynecologic Oncology (KSGO) has published the following editions on a regular basis to suggest the best possible standard care considering updated scientific evidence as well as medical environment including insurance coverage. The Guidelines Revision Committee was summoned to revise the second edition of KSGO practice gu...
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | CT Scan | Health | Hematology | Ovarian Cancer | Ovaries | Pathology | PET Scan | Study